Keywords: dutch, firms, introgene, u-bisys, merge, netherlands-based, biopharmaceutical
Dutch firms IntroGene and U-BiSys merge
Article | 03 July 2000
Two Netherlands-based biopharmaceutical companies, IntroGene BV andU-BiSys BV, have announced plans to merge, creating a new company, Crucell, which will ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
